


The status of paediatric medicines initiatives around the world—what has happened and what has not?

**Kalle Hoppu, Gabriel Anabwani,
Facundo Garcia-Bournissen, Madlen
Gazarian, Gregory L. Kearns, Hidefumi
Nakamura, Robert G. Peterson, et al.**

**European Journal of Clinical
Pharmacology**

ISSN 0031-6970
Volume 68
Number 1

Eur J Clin Pharmacol (2012) 68:1-10
DOI 10.1007/s00228-011-1089-1



 Springer

Your article is protected by copyright and all rights are held exclusively by Springer-Verlag. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author's version for posting to your own website or your institution's repository. You may further deposit the accepted author's version on a funder's repository at a funder's request, provided it is not made publicly available until 12 months after publication.

The status of paediatric medicines initiatives around the world—what has happened and what has not?

Kalle Hoppu · Gabriel Anabwani · Facundo Garcia-Bournissen · Madlen Gazarian · Gregory L. Kearns · Hidefumi Nakamura · Robert G. Peterson · Shalini Sri Ranganathan · Saskia N. de Wildt

Received: 31 March 2011 / Accepted: 9 June 2011 / Published online: 6 July 2011
 © Springer-Verlag 2011

Abstract

Purpose This review was conducted to examine the current status of paediatric medicines initiatives across the globe.

Methods The authors made a non-systematic descriptive review of current world situation.

Results Two regions, the United States (US) and the European Union (EU), and the World Health Organization (WHO) have introduced strong paediatric initiatives to improve children's health through improving access to better paediatric medicines. The experience from the US initiative indicates that it is

possible to stimulate development and study of paediatric medicines and provide important new information for improvement of paediatric therapy. The early results from the EU initiative are similarly encouraging. In Canada, Japan, Australia and other developed countries, specific paediatric medicines initiatives have been less extensive and weaker, with modest results. Disappointingly, current evidence suggests that results from clinical trials outside the US often do not benefit children in the country in which the trials were largely conducted. Pharmaceutical companies that have

K. Hoppu (✉)
 Hospital for Children and Adolescents and Dept. of Clinical Pharmacology, University of Helsinki and Poison Information Centre, Helsinki University Central Hospital,
 P.O. Box 790, 00029 Helsinki, Finland
 e-mail: kaarlo.hoppu@hus.fi

G. Anabwani
 Botswana-Baylor Children's Clinical Centre of Excellence,
 Gaborone, Botswana

F. Garcia-Bournissen
 Buenos Aires Children's Hospital "R Gutierrez",
 Buenos Aires, Argentina

M. Gazarian
 Paediatric Therapeutics Program, School of Women's and Children's Health, University of New South Wales and Sydney Children's Hospital, Randwick,
 Sydney, NSW, Australia

G. L. Kearns
 Departments of Pediatrics and Pharmacology,
 University of Missouri,
 Kansas City, MO, USA

G. L. Kearns
 Division of Pediatric Pharmacology and Medical Toxicology,
 The Children's Mercy Hospital,
 Kansas City, MO, USA

H. Nakamura
 Division for Clinical Trials, Clinical Research Center,
 National Center for Child Health and Development,
 Tokyo, Japan

R. G. Peterson
 Department of Pediatrics, Faculty of Medicine,
 University of British Columbia,
 Vancouver, BC, Canada

S. Sri Ranganathan
 Department of Pharmacology, Faculty of Medicine,
 University of Colombo,
 Colombo, Sri Lanka

S. N. de Wildt
 Intensive Care and Pediatric Surgery, Erasmus MC,
 Sophia Children's Hospital,
 Rotterdam, The Netherlands

Present Address:
 M. Gazarian
 School of Medical Sciences, Faculty of Medicine,
 University of New South Wales,
 Sydney, NSW, Australia

derived a financial benefit commensurate with the cost of doing the paediatric trials in one country do not seem to be making the results of these trials available to all countries if there is no financial incentive to the company. The WHO campaign 'make medicines child size' has produced substantive accomplishments in building improved foundations to improve mechanisms that will enhance children's access to critical medicines in resource-limited settings. However, practically all of this work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment.

Conclusions Although much still needs to be done, it's clear that with concerted efforts and appropriate resources, change is possible but slow. Retaining and fostering public and political interest in paediatric medicines is challenging, but pivotal for success.

Keywords Biomedical research · Legislation · Jurisprudence · Child · Drugs, investigational

Providing children better access to safe and effective medicines addressing their therapeutic needs appeared on the agenda of many countries during the last decade [1]. Pioneering legislation to address paediatric needs came into force in the United States (US) in 1997. The European Union's (EU) Paediatric Regulation and the unanimous adoption by the World Health Assembly of Resolution WHA60.20, 'Better medicines for children', followed in 2007 [2]. The duration these initiatives have been in force may be too short to expect that the problems of some 40 years of children being 'therapeutic orphans' [3] could have been abolished. However, it is long enough to expect some concrete results.

As members of the paediatric clinical pharmacology community representing many countries, our purpose in assembling this review was to examine the current status of paediatric medicines initiatives across the globe, reveal some of the associated challenges/problems and offer some perspective on future needs. We also explore whether the initiatives have spawned any new paediatric medicines initiatives around the world. However, we were not able to report on all developments, or lack of them, addressing paediatric therapeutic needs. For example initiatives addressing the promotion of rational use of medicines (RUM) are beyond the scope of this review. We focus on major initiatives demonstrating commitment of the whole society to narrow the old therapeutic gap between children and adults.

The US and EU legislative/regulatory initiatives


In response to the challenge of improving both the licensing and labelling of drug products for paediatric patients and

thereby facilitate access to accurate information and, in some cases, paediatric-friendly drug formulations, both the US and EU have developed significant regulations, the timeframe for which is depicted in Fig. 1. The US regulation has been in force for discrete 5-year periods, with two sunsets, emerging each time with a new name and modifications (Fig. 1). The EU regulation, still in its original form, benefitted during its development from the US experience. In essence, both regulations currently include a requirement part with a reward (on-patent medicines) and a voluntary part with an incentive (off-patent medicines) for paediatric development, both aimed at the pharmaceutical industry. To get the reward or incentive, data from paediatric studies have to be submitted to regulatory authorities for assessment of market authorisation or labelling change. The reward/incentive in both regions is primarily a 6-month extension of patent protection; a provision that, from a fiscal perspective, would appear at the surface to have been of greater benefit for drug manufacturers as opposed to paediatric patients per se [4]. For medicines without intellectual property protection, paediatric development is voluntary. The EU offers an incentive mainly in the form of a 10-year data protection, and in both regions some public funding is available for studies of off-patent medicines. More details on the paediatric initiatives are available from publications and official websites [5–8].

What have the EU and US paediatric regulations already achieved?

The regulatory evolution produced a true renaissance in paediatric clinical pharmacology and drug development in the U.S. As a result of the potential benefit afforded by extended marketing exclusivity, paediatric drug development was given greater emphasis and priority within the pharmaceutical corporate sector. As a result of an expanded number and scope of paediatric drug trials, the quantity and quality of information that could be translated to the labelling of approved drug products markedly increased. For a cohort of 365 trials performed for 153 medicines (December 1997–September 2007), 137 labelling changes resulted, 26% of which included the addition of safety information to improve paediatric medicines use [9]. During the most recent US regulation, the Food and Drug Administration Amendments Act (FDAAA), 305 studies were completed involving over 111,000 paediatric patients between September 2007 and September 2010 (Table 1). By February 2010, paediatric studies permitted over 350 labelling changes, and extended marketing exclusivity was granted for over 170 medicines [10].

Fig. 1 Timeframe of the US and EU paediatric regulations



The incentive of extended marketing exclusivity of a medicinal product for all approved indications (i.e. both adult and paediatric) has leveraged resources dedicated to the support of paediatric clinical trials in the private (corporate) sector. Data from studies of nine antihypertensive medicines submitted to the FDA from 1994 to 2004 show an average ratio of net economic return to cost (of performing required studies) of 17 (range 4–64.7) [11]. Such rates of return have made it economically feasible for pharmaceutical companies to dedicate resources to paediatric medicines development of products whose paediatric market place could be extremely small (e.g. antihypertensive drugs).

To date, more than 450 of 1,000 applications submitted for a Paediatric Investigation Plan (PIP; the regulatory ‘tool’ in the EU) or Waiver have received a positive opinion from the Paediatric Committee (PDCO) of the EMA [12]. About one-third related to product-specific waivers (the medicine does not need to be studied in children, e.g. no paediatric indication) [13], and two-thirds concerned a PIP. In contrast, as of January 2010, the proportion of paediatric

trials as a percentage of all clinical trials in Europe has increased only moderately (from 8.2 to 9.4% of all trials), reflecting the fact that paediatric trials requested by EMA are generally deferred (82%) years until after adult development [14]. So far, the new European regulation has resulted in only three medicines for which a market authorisation extension of 6 months was granted (losartan, caspofungin, anastrozole). No Paediatric Use Marketing Authorisation (PUMA), the incentive for off-patent medicines, has yet been authorised.

Paediatric regulations in other countries

During the last decade, the US and EU paediatric initiatives and the problems of children’s access to appropriate medicines have received wide exposure in professional journals and public media all around the world. In addition, the process leading to the WHA Resolution 60.20, endorsed by almost all governments of the world, also exposed policy makers to these problems. So have other governments followed the WHA resolution and taken steps to develop their own paediatric regulations, or are they just waiting for the US and EU to solve the problems?

Australia, Japan and Canada

If we look at legislative and regulatory reforms, development in Australia, Canada and Japan has been at best modest (Table 2). In Canada, there is a current provision in the Canadian Food and Drug Regulations that provides for a 6-month extension for data protection to innovator companies providing evidence to support a label indication for a product which has value in treating the paediatric age group.

In Japan, there is no comprehensive legislation to provide incentives and mandate development of paediatric

Table 1 Breakdown of Food and Drug Administration Amendments Act (FDAAA) paediatric studies completed between 27 September 2007 and 30 September 2010 [10]

Type of study	BPCA	BPCA + PREA	PREA	Total
Efficacy/safety	28	28	146	202
PK/safety	6	29	11	46
PK/PD	10	8	3	21
Safety	3	3	19	25
Other	0	0	11	11
Total	47	68	190	305

BPCA Better Pharmaceuticals for Children Act, PREA Pediatric Research Equity Act

Table 2 Current status of legislative/regulatory paediatric initiatives in some key high-income countries/economic areas around the world

Type of legislation	USA	EU	Japan	Canada	Australia
Legislation to provide incentive for study/development of medicines for children	In effect from 1997	In effect from 2007	Premium (higher price) for new (patent protected) medicines developed for children and for existing ones eliminating unapproved/off-label indications (2006–)	Regulation provides 6 month extension to 8 years of market exclusivity through data protection to innovator companies who provide evidence to support a label indication for a product which has value in treating the paediatric age group (2006–)	No
Legislation requiring study/development of medicines for children	In effect from 2003	In effect from 2007	No	No	No
Other legislative/regulatory measures to increase children's access to existing medicines	Creation of the FDA Office of Pediatric Therapeutics (1998)	Free scientific advice available from regulatory authorities	Government Study Group/Expert Panel on paediatric unlicensed and off-label medicines (established 2005, reorganised 2009)	No	Government Paediatric Medicines Advisory Group to provide advice on paediatric medicines needs/access, within existing legislative and regulatory frameworks (2007–)

medicines [15]. In contrast to the US and EU, Japan has a low penetration rate of generics, therefore extended patent protection for innovator companies may not be an effective option. The voluntary approaches tried, e.g. paediatric premium and extension of re-examination period, turned out not to be effective incentives [16]. In 2010, the price premium for promotion of new medicines creation and resolution of unapproved/off-label medicines was introduced as part of the new drug development promotion scheme. With this scheme, industries must comply with the request from the Ministry of Health, Labour and Welfare (MHLW)/the Study Group on Unapproved and Off-label Drugs of High Medical Need to get the premium for all their new innovative medicines. Development of 60 unapproved medicines and 122 off-label indications has been requested by the MHLW as of February 2011.

In Australia, paediatric-specific medicines initiatives have been proposed through professional and government advisory bodies since the mid-1990s. These address improvements in paediatric medicines research, regulation and public subsidy to improve children's access to appropriate medicines, coupled with systematic strategies to support quality use of medicines (QUM), a cornerstone of Australia's comprehensive National Medicines Policy (NMP) [17, 18]. Despite many years of advocacy and awareness of recent international initiatives, Australia still lacks any legislative and regulatory reforms addressing paediatric medicines. Although other initiatives in recent years have led to some improvements in children's access to needed medicines through public subsidy [19], there is as yet no explicit whole-of-government commitment to give high priority to children's medicines issues, with ongoing major gaps in needed initiatives (Tables 2 and 3) and lack of a well coordinated and resourced national strategy [18]. Strong professional advocacy is continuing on multiple fronts.

Other countries

The Korean Food and Drug Administration set up a task force team on off-label medicine use evaluation in April 2010. We are not aware of any other significant legislative or regulatory initiatives of the types described earlier in other developed countries of the world.

In middle and low income countries, effort needs to first be devoted to build or improve the legislative and regulatory framework necessary for regulatory oversight of paediatric clinical trials and regulatory assessment of paediatric medicines. The types of paediatric initiatives as described for some of the rich countries are otherwise not possible, children's access to medicines is compromised and risk of exploitation in clinical trials remains high [20].

In Latin America, regulatory agencies have embarked on the crucial effort to harmonize procedures and adhere to

Table 3 Current status of paediatric initiatives to help paediatric medicines research in some key high-income countries/economic areas around the world

Type of initiative	USA	EU	Japan	Canada	Australia
Dedicated funding for research/development of paediatric medicines	Primarily available through various institutes comprising the National Institutes of Health	EU (EU Framework Program), joint national (ERA-NET PRIOMEDCHILD 2010) and some national (the Netherlands 2009–2017)	No	No	No
National (regional) network to increase capacity for study of paediatric medicines	Pediatric Pharmacology Research Unit (PPRU) Network, 1994–2010; Clinical Translational Science Award (CTSA) Pediatric Pharmacology Consortium, 2008–2010 and NIH Pediatric Trial Network (PTN), 2010–2017	European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) consisting currently of 17 existing national and European networks and centres with specific expertise in performing studies in children (2011–)	Pediatric Clinical Trial Network is being established as a part of the activity of Japanese Association of Children's Hospitals and Related Institutions (JaCHRI)	No	No
Training/capacity building initiatives in the area of paediatric medicines research	National Institute of Child Health and Human Development (NICHD) support of individual fellows (1998–2010); supplementation of existing adult clinical pharmacology training programs (T32) and creation of two training programs (T32) dedicated to paediatric clinical pharmacology (2011)	Global Research in Paediatrics (GRIP), a Network of Excellence project funded by EU 7th Framework Program for 2011–2015 has about 40% of resources dedicated for training/capacity building internationally	Occasional short courses on paediatric clinical research funded by government grants	No	No

good clinical practice (GCP) guidelines. These initiatives [21] have led to the approval of a specific guideline for clinical trials in the paediatric population [22, 23], currently under discussion by individual member countries [24]. For developing regulatory capacity to handle paediatric medicines globally, the Paediatric Medicines Regulator's Network (PmRN) was recently set up by the WHO with representatives from national medicines regulatory authorities (NMRAs) from all regions, as part of the WHO's Better Medicines for Children initiative.

The WHO Better Medicines for Children initiative

The WHA60.20 Resolution 'Better Medicines for Children' adopted in May 2007 urges WHO Member States and the WHO to undertake many activities, such as improving paediatric medicines research, regulation, access and rational use [1, 2]. Early achievements have been impressive, particularly in view of the fact that the Member States did not provide any funding for the work. Progress has largely been possible due to a US\$9.7 million grant from the Gates Foundation to WHO and UNICEF in 2009. WHO has been spearheading a global campaign launched in

December 2007, 'Make Medicines Child Size', to reach the Better Medicines for Children resolution's goals, with an extensive list of the achievements to date [25].

The first, and probably most important, achievement has been the establishment of a Model List of Essential Medicines for Children (EMLc) [26, 27]. The Third EMLc has recently been adopted. Considering the importance of the WHO Essential Medicines concept to medicines access in resource-limited settings [28, 29], the significance of the EMLc should not be underestimated. WHO has also followed up with a Model Formulary for Children [30].

The majority of WHO's other achievements [25, 31] lay foundations for more concrete actions to follow, but some may develop to new international paradigms. These include work to develop the best method to estimate body weight easily and reliably for correct dosing for paediatric patients, and the suggested shift from liquid to flexible solid oral dosage forms as priority paediatric formulations [32].

At the country level, early results of this resolution have been seen in some African and Asian countries. In Sri Lanka, paediatric formulations and essential medicines for children have been included in the last two revisions of the National Essential Medicines [33, 34]. In India, the Indian Academy of Paediatrics has prepared an EMLc. Some

states in India have included paediatric formulations into their EML while others are in the process of doing so (personal communication).

Strengthening infrastructure and building capacity for research and development of paediatric medicines

Providing children with better medicines will require significantly more paediatric medicines research. This will require development of infrastructure, capacity building and funding. The US and EU paediatric initiatives are establishing new networks and expanding existing networks with specific expertise in performing paediatric clinical trials and providing dedicated funding for research and training (Table 3).

In anticipation of the need to create an integrated clinical trial platform to embrace the opportunities in paediatric drug development afforded by changes in regulations (Fig. 1), the US National Institutes of Health, through its Institute of Child Health and Human Development (NICHD), created the Pediatric Pharmacology Research Unit (PPRU) Network. Based on the performance of the PPRU Network (e.g. over 160 clinical trials, approximately 70% of which were sponsored by a pharmaceutical company and over 70% of which constituted a phase I or II study; unpublished data obtained from the PPRU Network Operations Center, September 2010), it could be argued that this model was successful as an early phase clinical trial platform.

To facilitate and support this transition in research focus and avoid duplication with efforts on behalf of the pharmaceutical industry, the NIH has refined its approach to facilitate paediatric clinical drug trials [35]. A NICHD-funded Pediatric Trial Network (PTN) has recently been created with a commitment of US\$95 million over the next 7 years. The PTN [36] will focus primarily on the study of off-patent medicines prioritized as part of the provisions of BPCA. NICHD anticipates the need to initiate activities in approximately five to ten therapeutic areas, with multiple approaches for each therapeutic area. Much of the work of the PTN over the next 7 years will be done in collaboration with the FDA.

In Europe, creation of a European network [European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)] of existing national and European networks and centres with specific expertise in performing studies in children was one of the obligations given to the EMA by the Paediatric Regulation [37, 38]. Launched in March 2011 Enpr-EMA aims to foster high-quality ethical research on medicines for use in children through networking and stakeholder collaboration with members from both within and outside the European Union. It remains to be

seen what will come out of the Enpr-EMA and when. However, EMA will not be funding the networks in any way. The 17 member networks have been established with mostly national grants and funding from public or private sources, including in some cases support from the pharmaceutical industry. Multinational speciality networks, such as the Paediatric European Network for the Treatment of AIDS (PENTA) and the Pediatric Rheumatology International Trials Organisation (PRINTO), have been successful in creating models for financing their infrastructure. The newer multi-speciality national networks have in many cases already run into problems, with an exception of the UK-MCRN, which receives considerable government support. After the national external support for establishment of some networks decreased or ceased, they have not, as expected, been able to rely on income from performing sponsored clinical trials from PIPs because these have included deferrals, and the real increase of paediatric trials is still to come [14].

The Canadian Institutes for Health Research (CIHR) has hosted a Drug Safety and Effectiveness Network, and—while not specifically mandated for research exclusively in maternal-child health—has recently awarded eight competitive research awards for applications focused on drug safety or effectiveness in reproductive or paediatric research topics. Canada also has a national research network, the Maternal, Infant, Child and Youth Research Network (MICYRN) [39], founded in 2006 as a collaborative network of 17 participating child/child-maternal academic health centres. Although not a paediatric clinical pharmacology or paediatric clinical trials network per se, the over 120 research networks of MICYRN formed by investigators working in the same specialty, on diseases, or populations have over 450 paediatric clinical trials recruiting at sites in Canada, which places Canada very high in national performance across the world. MICYRN is also participating in the European Enpr-EMA network.

In Japan, the Japanese Association of Children's Hospitals and Related Institutions (JaCHRI) established a paediatric clinical trial network in collaboration with other subspecialty networks. The National Center for Child Health and Development (NCCHD) is getting funding from the MHLW for the infrastructure and education for this JaCHRI clinical trial network.

In Australia a number of centres and national networks are involved in paediatric clinical trials and clinical research generally, supported by funding from a variety of sources. Unlike many other national research councils, the Australian National Health and Medical Research Council (NHMRC) does not have an explicit focus for paediatric and child health research. Despite wide professional support and many years of strong advocacy by various stakeholders for dedicated resources, national infrastructure

and capacity building specifically for paediatric medicines research, currently Australia still lacks these (Table 3). Although encouraging recent developments in national capacity building for clinical trials [40] are anticipated to also support paediatric clinical trials and medicines research, the lack of explicit policy commitments and accompanying funding continues to pose major barriers to significant progress.

Enrolling children in clinical trials is common in Latin America [41, 42], but most are run by international pharmaceutical corporations [42]. Investigator-initiated paediatric trials are less common in part due to significant costs and regulatory obstacles faced by independent investigators. Funding is limited and mostly for specific topics such as neglected diseases and common paediatric disorders, and rarely aimed at the development of medicines for children. A few agencies [e.g. TDR/WHO, Drugs for Neglected Diseases initiative (DNDi)] provide funds specifically for the development of paediatric medicines, but that are also restricted to specific areas such as neglected or emerging diseases [43, 44]. Some agencies (e.g. DNDi) provide funds specifically for the development of paediatric medicines.

India is well known for its strong generic pharmaceutical industry, which supplies generic medicines (including those for paediatric patients) throughout the developing world. Paediatric clinical trials for medicines intended to be marketed in more developed countries are to some extent conducted in India. The Clinical Trial Registry of India has registered 81 clinical trials in children from 2006 till 15 August 2010 [45]. In India, the WHO has dedicated funds for research, development of paediatric medicines and capacity building including building a national network. In South-Asia, as in other parts of the developing world, the funding priority is to provide access to paediatric medicines, and research is more focused on providing data on availability and use of paediatric medicines than on paediatric clinical trials. Not surprisingly, the major limitation in carrying out research is the lack of dedicated funding required to support it.

Will the countries without a strong paediatric initiative benefit from the initiatives elsewhere?

Disappointingly, evidence from Europe before the paediatric regulation [46], and from Australia and New Zealand [47] and Canada (unpublished) does not support the contention that children from developed countries without a strong financial reward have benefitted to any significant extent from the US initiative, at least in the form of an increase in paediatric labelling or availability of paediatric formulations. International companies do not appear to be

willing to voluntarily submit data collected in the US to support the authorisation of paediatric indications elsewhere. This is particularly disturbing when considering that 65% of the published studies conducted in 1998–2007 under the US regulations were conducted in at least one country outside the US, and 11% did not include any sites in the US [42].

The evidence seems clear; we live in a hostage environment. Countries without strong incentives/rewards for submission of paediatric data are unlikely to benefit in the form of increased paediatric labelling, even when the cost of the studies has already been covered by financial rewards from the US or EU, and despite the paediatric population of the country having contributed to these studies. In fact such countries, even rich ones such as Canada and Australia, run the risk of their paediatric population being exploited for the incentives available elsewhere.

Will the initiatives provide children access to the medicines they need?

The studies done so far, with the majority of data from the US, have resulted in improved understanding of the pharmacokinetics of medicines prescribed for children, important changes in dosing and in safety information [9, 48]. While all of the medicines/formulations studied under the US initiatives ostensibly had some demonstrable paediatric use, the fiscal attractiveness of 6 months of market exclusivity resulted in the study of many medicines within a given class that are widely used in infants and children (e.g. the proton pump inhibitors) and in some instances, specific medicines with extremely low paediatric use (e.g. alendronate, anagrelide, dorzolamide) [49]. In contrast, many very widely used and important paediatric medicines without patent life left remain to be sufficiently studied (e.g., clindamycin, fluconazole, metronidazole).

None of the medicines with market authorisation extension in Europe targets a major paediatric disease. The PIPs received by the EMA mainly concern medicines targeting adult diseases, which is in line with economic profit expected by companies [14]. For example, of 29 anticancer medicines authorised since 2007, only 6 have a full paediatric indication [50]. Usually a waiver in oncology is issued based on the histological type of disease, not based on a medicine's mechanism of action. However, the same medicines that may be effective in adult cancers also have the potential to benefit children with cancer. Of all PIPs approved, only 26 and 35% of medicines need to be studied in young infants and neonates respectively. As the major changes in PK are expected in the first 2 years of life, it is surprising, and also disappointing, that many medicines are still not studied in the most vulnerable population [13].

However, the initiatives have many additional beneficial effects. As a direct result of the increased activity in paediatric clinical trials over the last decade, development of high quality approaches for the study of medicines has dramatically increased the quality and quantity of knowledge generated (e.g. developmental differences in drug disposition and action and their effect on the dose-concentration-effect relationship; occurrence of age-specific adverse effects). The incorporation of new technologies such as pharmacogenomics into the context of a regulatory paediatric drug trial has enhanced our ability to study increasing biological complexity associated with ontogeny and disease and to use this information to transition paediatric therapeutics from a predominantly medicine-based orientation to a patient-based orientation (i.e. personalized medicine) [51]. The published data on efficacy and safety of medicines becoming available also have the potential to benefit national programs for rational use of medicines in the paediatric population worldwide.

A major benefit for children globally is illustrated by the improved access of children to HIV/AIDS medicines in resource-limited settings. For adults in developing countries the potential to access ARVs significantly improved when pharmaceutical companies in developing countries began to produce generic medicines at vastly reduced prices after 2001. For children, the reduced drug costs unmasked lack of appropriate paediatric formulations as a key impediment [52]. Increased international support and funding resulted in research evidence that use of generic adult fixed drug combinations could provide an interim solution for scaling up of ARV treatment in children [53, 54]. As a result the proportion of children in need of ARVs in low- and middle-income countries who received them rose from 7% in 2005 to 29% at the end of 2009 (2009 adult coverage was 36%) [55]. Although much more needs to be done, these developments indicate that change is possible. However, it is also clear that even modest improvements take decades not years to achieve.

Conclusions

Currently only two regions, the US and EU, have strong paediatric initiatives containing both incentives and requirements for the development and regulatory assessment of paediatric medicines. These initiatives express a strong commitment by governments and the whole society of these regions for change. The US experience to date shows that it is possible to stimulate development and study of paediatric medicines and provide important scientific data for improvement of paediatric therapy, albeit not yet optimally aligned with priority child health needs. Clearly the incentives work better for new medicines still under patent

protection. In contrast, for off-patent medicines additional measures such as dedicated public funding are needed. The weaker paediatric initiatives some countries have tried have not been successful and indicate that broad societal commitment to change is still missing in many regions. So far it also seems that countries without strong paediatric initiatives have not benefitted substantially from developments elsewhere. Underdeveloped legal and regulatory frameworks and the weak economy of middle to low-income countries makes the types of paediatric initiatives discussed here unreachable. Although some indirect benefits have been noted in such countries, available evidence also indicates a clear risk of exploitation of their paediatric population for clinical trials performed for countries with strong initiatives.

The WHO Better Medicines for Children initiative has done a substantial amount of work in building and improving the foundations for children's access to critical medicines in resource-limited settings. However, practically all of the WHO work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment.

Even in the best possible scenario it is likely to take decades for the current paediatric initiatives to significantly narrow the gap between paediatric and adult populations in availability and access to medicines of comparable quality, efficacy and safety. Although much still needs to be done, developments to date indicate that with concerted efforts and appropriate resources, change is possible but slow. One of the biggest challenges is how to retain and foster further development of public and political interest in paediatric medicines in existing and new regions, which is pivotal for longer term funding and ultimate success of these initiatives globally. Achieving well coordinated, well resourced and focused national strategies for paediatric medicines research, regulation, access and rational use will require strong and sustained advocacy on multiple fronts highlighting these needs as priorities for all regions of the world.

Acknowledgements We thank Professor Gita Batmanabane, India, for providing information on the situation in India. Dr Kalle Hoppu and Dr Hidefumi Nakamura are members of the Global Research in Paediatrics (GRIP) consortium which has received research funding from the European Union 7th Framework Program.

References

1. Hoppu K (2008) Paediatric clinical pharmacology: at the beginning of a new era. *Eur J Clin Pharmacol* 64(2):201–205
2. World Health Assembly (2007) Resolution WHA60.20 'Better medicines for children'
3. Shirkey H (1968) Therapeutic orphans. *J Pediatr* 72(1):119–120
4. Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, Burggraaf J (2007) Stimulation programs for pediatric drug

- research—do children really benefit? *Eur J Pediatr* 166(8):849–855. doi:10.1007/s00431-006-0381-z
5. US FDA (2003) Pediatric Research Equity Act. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf>
 6. European Commission (2006) Regulation (EC) no 1901/2006 of the European parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) no 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (2006). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf
 7. Dunne J (2007) The European regulation on medicines for paediatric use. *Paediatr Respir Rev* 8(2):177–183
 8. Mathis L, Rodriguez W (2009) Drug therapy in pediatrics: a developing field. *Dermatol Ther* 22(3):257–261. doi:10.1111/j.1529-8019.2009.01239.x
 9. Benjamin DK Jr, Smith PB, Sun MJ, Murphy MD, Avant D, Mathis L, Rodriguez W, Califf RM, Li JS (2009) Safety and transparency of pediatric drug trials. *Arch Pediatr Adolesc Med* 163(12):1080–1086. doi:10.1001/archpediatrics.2009.229
 10. US FDA Office of Pediatric Therapeutics (2011) Breakdown of FDAAA completed pediatric studies. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm190622.htm>. Accessed 20 January 2011
 11. Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Murphy MD, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS (2008) The economic returns of pediatric clinical trials of antihypertensive drugs. *Am Heart J* 156(4):682–688. doi:10.1016/j.ahj.2008.05.001
 12. European Medicines Agency (2010) European Medicines Agency receives 1,000th application for a Paediatric Investigation Plan or Waiver. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001128.jsp&menu=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. Accessed 29 November 2010
 13. European Medicines Agency (2010) Report to the European Commission. http://ec.europa.eu/health/files/paediatrics/article_50_report2010.pdf. Accessed 19 January 2011
 14. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A (2011) Three years of paediatric regulation in the European Union. *Eur J Clin Pharmacol* 67(3):245–252. doi:10.1007/s00228-011-0997-4
 15. Drug Therapy Committee of the Japan Pediatric Society (2000) Survey of the current state of pediatric drug use in Japan (1994–6). *Pediatr Int* 42(1):109–113
 16. Nakamura H, Ozaki M (2010) Facilitation of paediatric research in Japan. In: Rose K, van den Acker JN (eds) *Guide to paediatric drug development and clinical research*. Karger, Basel, pp 15–22
 17. Department of Health and Ageing (2008) National medicines policy advisory structures and priorities. <http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-advisory-structure.htm>. Accessed 6 December 2010
 18. Gazarian M (2009) Delivering better medicines to children: need for better integration between the science, the policy, and the practice. *Paediatr Drugs* 11(1):41–44
 19. Department of Health and Ageing (2008) Paediatric medicines advisory group. <http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-pmag>. Accessed 6 December 2010
 20. Hoppu K, Sri Ranganathan S, Dodoo ANO (2011) Realities of paediatric pharmacotherapy in the developing world. *Arch Dis Child*. doi:10.1136/adc.2009.180000
 21. Pan American Health Organization (2010) Network for drug regulatory harmonization website. http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=1156&Itemid=513. Accessed 8 December 2010
 22. PANDRH GPC committee (2008) V Pan American conference on drug regulatory harmonization: preliminary report, conclusions and recommendations. http://new.paho.org/hq/dmdocuments/2009/V-Conf-PANDRH_Draft-Report.pdf. Accessed 8 December 2010
 23. PANDRH GPC Committee (2008) PANDRH good clinical practices workgroup—draft under discussion—guide for conducting clinical studies in pediatric populations. http://new.paho.org/hq/dmdocuments/2008/VConferencePANDRH_4_ClinicalPractices.pdf. Accessed 8 December 2010
 24. Pan American Health Organization (no year) Guia para realizacion de ensayos clinicos en poblacion pediatrica—borrador en discusion. <http://www.annat.gov.ar/publicaciones/BPC-Investpediatrica.pdf>. Accessed 8 December 2010
 25. WHO (2007) WHO global campaign: make medicines child size. <http://www.who.int/childmedicines/en/index.html>. Accessed 7 January 2011
 26. World Health Organization (2008) The selection and use of essential medicines. Report of the WHO Expert Committee, October 2007 (including the Model List of Essential Medicines for Children). Technical report series, vol 950. WHO, Geneva
 27. World Health Organization (2009) The selection and use of essential medicines. Report of the WHO Expert Committee, 2009 (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List of Essential Medicines for Children), Technical report series, vol 958. WHO, Geneva
 28. Hill S, Gray A, Weber M (2007) Setting standards for essential children's medicines. *Bull World Health Organisation* 85(9):650
 29. Hoppu K, Hogerzeil HV (2011) Global aspects of drug development. In: Seyberth H, Rane A, Schwab M (eds) *Handbook of experimental pharmacology*, vol 205. Pediatric clinical pharmacology. Springer, Berlin
 30. WHO (2010) WHO model formulary for children 2010. WHO, Geneva
 31. WHO (2010) Report of WHO second partners meeting on better medicines for children (Geneva, October 2010). http://www.who.int/entity/childmedicines/progress/partners_meeting_2010.pdf. Accessed 7 January 2011
 32. WHO (2008) WHO report of the informal expert meeting on dosage forms of medicines for children. http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf
 33. Ministry of Healthcare and Nutrition and Department of Pharmacology (2006) National list of essential medicines, Sri Lanka, 3rd revision
 34. Ministry of Healthcare and Nutrition and Department of Pharmacology (2009) National list of essential medicines, Sri Lanka, 4th revision
 35. Vitiello B (2008) Recent developments and strategies in pediatric pharmacology research in the USA. *Child Adolesc Psychiatry Ment Health* 2(1):36. doi:10.1186/1753-2000-2-36
 36. National Institutes of Health (2010) Pediatric trials network. <http://bpc.nichd.nih.gov/clinical/network/index.cfm>. Accessed 4 December 2010
 37. European Medicines Agency (2011) European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000303.jsp&menu=menus/partners_and_networks/partners_and_networks.jsp&mid=WC0b01ac05801df74a. Accessed 10 January 2011
 38. European Medicines Agency (2011) Enpr-EMA membership. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/q_and_a/q_and_a_detail_000108.jsp&jsenabled=true. Accessed 10 January 2011
 39. Maternal, Infant, Child and Youth Research Network (MICRYN) (2011) Home page. www.micyrn.ca. Accessed 10 January 2011
 40. Department of Innovation, Industry, Science and Research (2011) Clinical Trials Action Group (CTAG). <http://www.innovation.gov.au/Industry/PharmaceuticalsandHealthTechnologies/ClinicalTrials>ActionGroup/Pages/default.aspx>. Accessed 19 January 2011

41. US NIH (2010) ClinicalTrials.gov. www.clinicaltrials.gov. Accessed 8 December 2010
42. Pasquali SK, Burstein DS, Benjamin DK Jr, Smith PB, Li JS (2010) Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. *Pediatrics* 126:e687–e692. doi:10.1542/peds.2010-0098
43. Drugs for Neglected Diseases Initiative (2010) Home page. <http://www.dndi.org/>. Accessed 8 December 2010
44. TDR (2011) Research on neglected priority needs. <http://apps.who.int/tdr/svc/research>. Accessed 19 January 2011
45. Manikandan S, Jayanthi M, Sivagnanam G (2011) Clinical trials in children: an assessment of the information in the Clinical Trials Registry of India (CTRI). *Indira Gandhi Medical College & Research Institute, Pondicherry*
46. European Commission, DG Enterprise (2004) Extended impact assessment. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/paediatrics/docs/extended_impact_assessment_final_3_september_en.pdf. Accessed 19 January 2011
47. Grieve J, Tordoff J, Reith D, Norris P (2005) Effect of the Pediatric Exclusivity Provision on children's access to medicines. *Br J Clin Pharmacol* 59(6):730–735
48. Roberts R, Rodriguez W, Murphy D, Crescenzi T (2003) Pediatric drug labeling. Improving the safety and efficacy of pediatric therapies. *JAMA* 290(7):905–911
49. US FDA (2011) Pediatric exclusivity granted. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM223058>. Accessed 20 January 2011
50. Vassal G (2009) Will children with cancer benefit from the new European Paediatric Medicines Regulation? *Eur J Cancer* 45(9):1535–1546. doi:10.1016/j.ejca.2009.04.008
51. Leeder JS, Kearns GL, Spielberg SP, van den Anker J (2010) Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. *J Clin Pharmacol* 50(12):1377–1387. doi:10.1177/0091270009360533
52. Yogev R (2005) Balancing the upside and downside of antiretroviral therapy in children. *JAMA* 293(18):2272–2274. doi:10.1001/jama.293.18.2272
53. Natu SA, Daga SR (2007) Antiretroviral therapy in children: Indian experience. *Indian Pediatr* 44(5):339–343
54. O'Brien DP, Sauvageot D, Zachariah R, Humblet P (2006) In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. *AIDS* 20(15):1955–1960. doi:10.1097/01.aids.0000247117.66585.ce
55. WHO/UNAIDS/UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. http://www.who.int/hiv/pub/2010progressreport/report/en/index.html%22%20%5Ct%20%22_blank. Accessed 15 November 2010

Pediatric Labeling Changes through February 25, 2011

This table highlights key pediatric information from the studies submitted in response to pediatric legislative initiatives (see below). Biologics have a solid dot (●) by the proper name. The table presents the most recent information first and it is searchable (e.g., Trade Name, Generic Name).

N=404

n= 368 with new pediatric studies; n=36 with no new pediatric studies (NNPS)

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics●) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
1.	1/30/2011	MENVEO	Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine●	Active immunization to prevent invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroups A, C, Y and W-135		See Package Insert for new information on biologics	P	Novartis	NA	
2.	1/18/2011	Natroba Topical Suspension	spinosad	Treatment of head lice infestation in patients 4 years of age and older.		<ul style="list-style-type: none"> ● Safety and effectiveness have been established in pediatric patients 4 years of age and older ● Safety in pediatric patients < 4 years has not been established. ● Not recommended in pediatric patients< 6 months because of the potential for increased systemic absorption ● Natroba contains benzyl alcohol which has been associated with serious adverse reactions and death in neonates and low birth-weight infants. Premature and low-birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity ● Information on clinical trials, adverse reactions ● New drug 	P	ParaPRO	NA	
3.	12/22/2010	GARDASIL	Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant●	Prevention of anal cancer and associated precancerous lesions caused by HPV types 16 and 18		See Package Insert for new information on biologics	P	Merck	NA	✓

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics®) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N P S
4.	12/21/2010	INOMax for Inhalation	nitric oxide	Prevention of bronchopulmonary dysplasia		<ul style="list-style-type: none"> • INOMax is not indicated for prevention of BPD in preterm neonates ≤ 34 weeks gestational age. • Efficacy for the prevention of BPD in preterm infants was not established in three double-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants • Information on clinical trials, adverse reactions 	B	INO Therapeutics	11/2/2010	
5.	12/15/2010	Uroxatral extended-release tablets	alfuzosin	Elevated detrusor leak point pressure of neurologic origin	<u>Labeling</u>	<ul style="list-style-type: none"> • Uroxatral is not indicated for use in the pediatric population • Efficacy was not demonstrated in a randomized, double-blind, placebo-controlled, efficacy and safety trial conducted in 172 patients ages 2 to 16 years using pediatric formulations 	B	sanofi-aventis	9/7/2010	
6.	11/19/2010	Moxeza ophthalmic solution	moxifloxacin hydrochloride	Bacterial conjunctivitis	<u>Labeling</u>	<ul style="list-style-type: none"> • Approved for use in patients 4 months and older • The safety and effectiveness have not been established in patients <4 months of age • There is no evidence that the ophthalmic administration of moxifloxacin has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals • Information on clinical study, adverse reactions • New dosage form 	P	Alcon	NA	
7.	11/10/2010	Vyvanse	lisdexamfetamine	ADHD	<u>Labeling</u>	<ul style="list-style-type: none"> • Expanded indication to include adolescent patients ages 13-17 years; previously approved for use in 6-12 years • Most common adverse reactions were decreased appetite, insomnia, and decreased weight • Information on clinical trial, adverse reactions 	P	Shire	NA	
8.	11/2/2010	Ofirmev Injection	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	<u>Labeling</u>	<ul style="list-style-type: none"> • The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. • The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age. 	P	Cadence Pharms	NA	

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics*) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N N P S
						<ul style="list-style-type: none"> The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and older Most common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis. Information on dosing, clinical studies, adverse reactions and PK parameters New dosage form and route of administration 				
9.	10/21/2010	Lo Loestrin Fe	norethindrone acetate/ ethinyl estradiol	Prevention of pregnancy	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and efficacy have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents <18 years and for users ≥18 years Use before menarche is not indicated New dose and dosing regimen 	P	Warner Chilcott	NA	✓
10.	10/5/2010	Aridol Powder for Inhalation	mannitol	Assessment of bronchial hyperresponsiveness in patients without clinically apparent asthma	<u>Labeling</u>	<ul style="list-style-type: none"> New indication in patients 6 years and older Efficacy assessed in a total of 246 children and adolescents 6 to 17 years in 2 clinical trials Bronchial challenge testing should not be performed in children < 6 years due to their inability to provide reliable spirometric measurements Adverse events similar to adults Information on adverse events and clinical studies New indication, dosage form, and route of administration 	P	Pharmaxis	NA	
11.	9/28/2010	Kapvay Extended Release Tablets	clonidine	Treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications	<u>Labeling</u>	<ul style="list-style-type: none"> New indication in children 6 years and older Efficacy is based on 2 clinical trials in children and adolescents 6 -17 years Kapvay has not been studied in children with ADHD < 6 years Kapvay can cause dose related decreases in blood pressure and heart rate 	P	Shionogi	NA	

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics®) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N P S
						<ul style="list-style-type: none"> Common adverse events reported in clinical trials included somnolence, fatigue, upper respiratory tract infection irritability, throat pain, insomnia, nightmares, emotional disorder. In fixed dose pediatric monotherapy study, 31% of patients treated with 0.4 mg/day and 38% treated with 0.2 mg/day vs 7% of placebo treated patients reported somnolence. Kapvay is an extended-release tablet formulation of clonidine; therefore, it is not to be used interchangeably with the immediate-release formulation Information on adverse events, and clinical trials New indication 				
12.	9/24/2010	Beyaz	drospirenone/ ethinyl estradiol	Prevention of pregnancy; premenstrual dysphoric disorder; moderate acne vulgaris ≥14 years who have achieved menarche; to raise folate levels in a pregnancy conceived while on or shortly after discontinuing the product	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and efficacy have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents <18 years and for users ≥18 years Use before menarche is not indicated New combination 	P	Bayer	NA	✓
13.	9/8/2010	Protopam	pralidoxime	Treatment of poisoning due to organophosphates (e.g., nerve agents)	<u>Labeling</u>	<ul style="list-style-type: none"> Expanded indication from adults to pediatrics Efficacy extrapolated from adult population and supported by nonclinical studies, PK studies in adults and experience in the pediatric population Information on IV and IM dosing, and adverse events 	P	Baxter	NA	✓
14.	9/3/2010	Zyrtec Allergy Orally Disintegrating Tablets	cetirizine	Temporary relief of symptoms due to hay fever or other upper respiratory allergies		<ul style="list-style-type: none"> Approved for use in 6 years and older No clinical studies submitted New dosage form 	P	McNeil Consumer Healthcare	NA	✓

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics®) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N N P S
				OTC						
15.	8/27/2010	Augmentin XR	amoxicillin/clavulanate potassium	Community-acquired pneumonia or acute bacterial sinusitis	Labeling	<ul style="list-style-type: none"> Expanded indication from adults to children weighing ≥ 40 kg who are able to swallow tablets Use in children is supported by evidence from trials of adults with additional data from a pediatric PK study Adverse events similar to adults Information on dose, and PK parameters Information added to Clinical Pharmacology and Pediatric Use 	P	GlaxoSmithKline	NA	
16.	8/13/2010	ella	ulipristal acetate	Prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure	Labeling	<ul style="list-style-type: none"> Safety and efficacy have been established in women of reproductive age. Safety and efficacy are expected to be the same for post pubertal adolescents <18 years and for users 18 years and older. Use of ella before menarche is not indicated New drug 	P	Laboratoire HRA Pharma	NA	✓
17.	7/28/2010	Lastacraft Ophthalmic Solution	alcaftadine	Prevention of itching associated with allergic conjunctivitis.	Labeling	<ul style="list-style-type: none"> Safety and effectiveness in patients >2 years were established in controlled clinical trials Safety and effectiveness in pediatric patients < 2 years have not been established New drug 	P	Vistakon Pharmaceuticals,	NA	
18.	6/29/2010	Daytrana	methylphenidate	ADHD	Labeling	<ul style="list-style-type: none"> Expanded pediatric indication to include adolescent patients ages 13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority 	P	Shire	NA	

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics®) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N N P S
						<p>of patients had erythema at the application site</p> <ul style="list-style-type: none"> Information on PK parameters, Adverse Event profile and clinical studies 				
19.	6/22/2010	Isopto Carpine	pilocarpine hydrochloride	Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; management of acute angle closure glaucoma; prevention of postoperative elevated IOP associated with laser surgery and induction of miosis	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and effectiveness in pediatric patients have been established Not recommended in pediatric patients diagnosed with glaucoma due to anterior segment dysgenesis or uveitis Caution is advised in pediatric patients with primary congenital glaucoma for control of IOP as cases of a paradoxical increase in IOP have been reported. Adverse events similar to adults New dosage form 	P	Alcon	NA	✓
20.	6/22/2010	Dulera Inhalation Aerosol	mometasone furoate and formoterol fumarate	Asthma	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and effectiveness have been established in patients 12 years and older in 3 clinical studies Safety and efficacy have not been established in children <12 years Data from clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients Information on adverse events and clinical studies New combination 	P	Schering	NA	

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N P S
21.	6/3/2010	Zylet	loteprednol etabonate and tobramycin	Eye lid inflammation	<u>Labeling</u>	<ul style="list-style-type: none"> Efficacy was not demonstrated in a study of pediatric patients 0-6 years 	P	Bausch and Lomb	NA	
22.	5/27/2010	Advil Congestion Relief	ibuprofen /phenylepherine HCl	Temporary relief of symptoms associated with cold and flu		<ul style="list-style-type: none"> Indicated for use in children 12 years and older Approval and age range based on monograph for decongestants and previous studies for ibuprofen Do not use in children < 12 years because this product contains too much medication for this age New drug 	P	Wyeth	NA	✓
23.	5/26/2010	Nasonex	mometasone	Nasal congestion associated with seasonal allergic rhinitis	<u>Labeling</u>	<ul style="list-style-type: none"> New indication in pediatric patients 2 years and older Safety and effectiveness evaluated in 3 clinical studies in 12 years and older. Use in pediatric patients 2 - 11 years is supported by data from other pediatric clinical studies Safety and effectiveness for any use in patients < 2 years have not been established Information on dosing, adverse reactions, and clinical studies in 12 years and older New indication 	P	Schering-Plough	NA	
24.	5/18/2010	Zymaxid	gatifloxacin	Bacterial conjunctivitis	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and effectiveness have been demonstrated in clinical trials for the treatment of bacterial conjunctivitis in pediatric patients 1 year and older The safety and effectiveness in infants < 1year have not been established Information on adverse reactions and clinical trials New drug 	P	Allergan	NA	

	Pediatric Labeling Date	Trade Name	Generic or Proper (Biologics®) Name	Indications Studied	Product Labeling	Labeling Changes	BPCA (B)/ PREA (P)/ Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	N P S
25.	5/13/2010	Taxotere	docetaxel	Solid Tumors	<u>Labeling</u>	<ul style="list-style-type: none"> Efficacy in pediatric patients as monotherapy or in combination has not been established. Taxotere has been studied in a total of 289 pediatric patients: 239 in 2 trials with monotherapy and 50 in combination treatment with cisplatin and 5-fluoruracil The overall safety profile in pediatric patients receiving monotherapy or combination treatment was consistent with the safety profile in adults Information on dosing, clinical trials and PK parameters 	B	Sanofi-aventis	3/17/2010	
26.	5/7/2010	Omnaris	ciclesonide	Postmarketing study	<u>Labeling</u>	<ul style="list-style-type: none"> Information on clinical study to assess effect of orally inhaled ciclesonide on growth 	P	Sepracor	NA	
27.	5/6/2010	Natazia	estradiol valerate and estradiol valerate/dienogest	Prevention of pregnancy	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and efficacy have been established in women of reproductive age. Safety and efficacy for post pubertal adolescents < 18 are expected to be the same as for 18 years and older Use of this product before menarche is not indicated New drug 	P	Bayer	NA	✓
28.	4/12/2010	Pancreaze	pancrelipase	Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions	<u>Labeling</u>	<ul style="list-style-type: none"> Safety and efficacy assessed in 2 studies that included patients 6-30 months and 8--17 years Safety and efficacy for use in all pediatric age groups based on information from the literature and clinical experience with different formulations of pancrelipase containing the same active ingredient High doses of pancreatic enzyme products have been associated with fibrosing colonopathy in children <12 years of age Adverse reactions similar to adults Capsule should be swallowed whole. For infants or patients unable to swallow intact 	P	Ortho-McNeil-Janssen	NA	